Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 12/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768482 | 0.83 | GRM2 (0.38) | CA2PARP1 | |
| SCHEMBL2766273 | 0.80 | STS (0.43) | STSCA2CA9CA1CA7 | |
| SCHEMBL2767117 | 0.77 | MIF (0.44) | PARP1 | |
| SCHEMBL2783566 | 0.76 | DRD3 (0.46) | PARP1 | |
| SCHEMBL3546808 | 0.75 | CA2 (0.45) | STSCA2CA9CA1CA7 | |
| SCHEMBL3543484 | 0.75 | STS (0.40) | STSCA2CA9CA1CA7 | |
| SCHEMBL3548915 | 0.75 | STS (0.40) | STSCA2CA9CA1CA7 | |
| SCHEMBL3545608 | 0.75 | MIF (0.46) | STSCA2CA9CA1CA7 | |
| SCHEMBL2784133 | 0.73 | CA2 (0.42) | STSCA2CA9CA1CA12 | |
| SCHEMBL3544385 | 0.73 | MIF (0.44) | STSCA2CA9CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3142665-B1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | APAXEN (BE) | 2021-01-20 | — | — | EP | disclosed |
| US-10071080-B2 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIFCARE (FR) | 2018-09-11 | — | — | US | disclosed |
| EP-2944310-B1 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIFCARE (FR) | 2018-03-21 | — | — | EP | disclosed |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| EP-3142665-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Mifcare (FR) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015173433-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIFCARE (FR) | 2015-11-19 | — | — | WO | disclosed |
| EP-2944310-A1 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | Mifcare (FR) | 2015-11-18 | — | — | EP | disclosed |
| US-7795251-B2 | 3,4-dihydro-benzo[e][1,3]oxazin-2-ones | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| EP-1805170-B1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-7378416-B2 | MIF-inhibitors | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| EP-1874742-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070219189-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2007-09-20 | — | — | US | disclosed |
| EP-1805170-A1 | MIF-INHIBITORS | Novartis AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006108671-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006045505-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | CYP2C8, CYP2C18, CYP4B1 | STS 1186/4885CA2 1198/4885CA9 1774/4885 |
| US-20070219189-A1 | MIF-INHIBITORS | MIF, FOXM1, CCR8 | STS 1775/4885CA2 2160/4885CA9 1041/4885 |
| US-10071080-B2 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIF, CCL11, PGF | STS 1067/4885CA2 488/4885CA9 1062/4885 |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIF, CCL11, PGF | STS 1067/4885CA2 488/4885CA9 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.